Company Description
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases.
It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.
The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy.
It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand.
The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.
Country | United States |
IPO Date | Aug 8, 2019 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 120 |
CEO | Dr. Robert Joseph Hariri M.D., Ph.D. |
Contact Details
Address: 170 Park Avenue Florham Park, New Jersey United States | |
Website | https://www.celularity.com |
Stock Details
Ticker Symbol | CELU |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001752828 |
CUSIP Number | 151190105 |
ISIN Number | US1511902041 |
Employer ID | 83-1702591 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Robert Joseph Hariri M.D., Ph.D. | Founder, Chief Executive Officer & Chairman |
David C. Beers C.F.A. | Chief Financial Officer |
Carlos Ramirez | SVice President of Investor Relations |
John R. Haines | Senior EVice President, Global Manager & Chief Administrative Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 06, 2024 | 10-Q | Quarterly Report |
Dec 02, 2024 | 8-K | Current Report |
Nov 29, 2024 | 8-K | Current Report |
Nov 19, 2024 | DEF 14A | Filing |
Nov 15, 2024 | NT 10-Q | Filing |
Nov 08, 2024 | 8-K | Current Report |
Nov 07, 2024 | 8-K | Current Report |
Nov 07, 2024 | 10-Q | Quarterly Report |
Oct 25, 2024 | 8-K | Current Report |
Oct 21, 2024 | 8-K | Current Report |